The abbreviations are used: GFP, green fluorescent protein; MTX, methotrexate; PCR, polymerase chain reaction; PBS, phosphate-buffered saline; HPLC, high performance liquid chromatography; ESI-MS, electrospray mass spectrometry.
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protein was eluted with MxeC buffer, the peak fractions were pooled, and concentrated with Centriprep-10 centrifugal concentrators (Millipore, Germany). Finally, the protein solution was incubated for another 3 hours at 25°C to allow the complete formation of the GFP chromophore.
Homogeneity of the protein was analyzed by SDS-PAGE and mass spectrometry, and concentration was determined by UV-Vis spectroscopy.
Purification of recombinant polyoma VP1 -E.coli BL21 cells were grown at 37°C in LB medium containing 70 µg/ml kanamycin. Expression of VP1 was induced by the addition of 1 mM IPTG. After continued cultivation for 5 hours, the cells were harvested, resuspended in P-A buffer (20 mM Tris/HCl, 2 mM EDTA, 6 mM DTT, 5 % glycerol, pH 8.5 ) and lysed at 800 bar using a gaulin LAB 1000 homogenizer. Cell debris was removed by centrifugation at 15.000 × g for 2 hours and 4°C, and VP1 was captured from the supernatant by an anion exchange column (Poros, Applied Biosystems, Germany) previously equilibrated with P-A buffer. After elution of VP1 from the column by a linear gradient of NaCl from 5 mM to 1 M, the protein was dialyzed against QS-A buffer (20 mM ethanol amine, 2 mM EDTA, 6 mM DTT, 5 % glycerol, pH 10.5) over night. The VP1-solution was applied to a Q-Sepharose column (Amersham Biosciences, Germany) and eluted again by a linear gradient of NaCl to 1 M. Afterwards, the protein was dialyzed against L1 buffer (50 mM sodium phosphate, 2 mM EDTA, 6 mM DTT, 150 mM NaCl, 5 % glycerol, pH 7.0). The final step of the VP1 purification was a size exclusion chromatography by which aggregates of VP1 were removed. Homogeneity of the protein was checked by SDS-PAGE, photon correlation spectroscopy (PCS) and mass spectrometry.
Protein concentration was determined by UV-Vis spectroscopy.
Expression and purification of VP2-SEt -VP2-SEt was expressed as an N-terminal fusion with the
Mxe intein/chitin-binding domain from expression vector pTXB1/VP2A8 in E.coli BL21(DE3) as described for GFP-VP2(A). Cells were harvested and the pellets were stored at -80°C. After thawing cell pellets on ice, which were obtained from 12 litres of culture volume, cells were resuspended in 125 ml of buffer A (20 mM HEPES, 0.5 M NaCl, 1 mM EDTA, 10 mg/ml DNAse, pH 6.8) and broken by 5 passages through a gaulin LAB 1000 homogenizer at 800 bar. The resulting suspension was centrifuged at 39000 × g for 45 minutes, the clarified supernatant was loaded onto a chitin column, washed with 10 CV buffer B (20 mM HEPES, 0.5 M NaCl, 1 mM EDTA, 0.1% Triton X100, pH 6.8) and cleaved with buffer C (2% [v/v] ethanethiol, 50 mM sodium phosphate, 200 mM sodium chloride, 1 mM EDTA, pH 6.8) over night at room temperature. After elution according to the instruction manual, the protein was isolated by preparative HPLC (Agilent SB C18 column, solvent system see above). In an HPLC-MS re-analysis of the product fraction, VP2-SEt was found to be > 98% pure. 
Synthesis of dipeptidelinker -MTX-Boc-Cys(Trt)-Lys(Fmoc)
-
Formation of capsoids from VP1 pentamers and VP2 anchor constructs containing GFP or MTX -
For the assembly of capsoids, DTT was removed from the VP1 pentamer solution with a desalting column (HiPrep 26/10, Amersham Biosciences; column volume 53 ml, flow rate 2 ml/min) equilibrated with KB1 buffer (50 mM sodium phosphate, 150 mM NaCl, 2 mM EDTA, 5 % glycerol, pH 6.8).
Structural integrity and concentration of the desalted pentamers were determined by PCS and UV-Vis spectroscopy. VP1 pentamers were incubated with a 7 fold molar excess of GFP-VP2(A) or with a 6
fold molar excess of VP2(B)-MTX for 1 hour at room temperature, respectively. Afterwards, assembly of the pentamers was initiated by adding KB2 buffer (10 mM Tris/HCl, 150 mM NaCl, 5 % glycerol, 3 M (NH 4 ) 2 SO 4 , pH 8.0) to a final ammonium sulphate concentration of 250 mM. After incubation for 30 minutes at 25 °C, the formed capsoids were oxidized by the addition of KB3 (400 mM GSSG in KB2) to a final GSSG concentration of 7.2 mM. Afterwards, the protein was dialyzed over night at 25 °C against PBS (Biochrom KG, Germany) containing 0.7 mM CaCl 2 . The excess of non-assembled VP2-anchor construct was removed by size exclusion chromatography (SEC) using a Superdex 200HR 10/30 column (flow rate 0.5 ml, Amersham Biosciences). A precipitation with polyethylene glycole (10% PEG 3000, Sigma-Aldrich) was performed in order to concentrate the capsoids for cell culture experiments.
Photon correlation spectroscopy (PCS) -Particle sizing was performed at 25 °C using a High
Performance Particle Sizer (ALV-NIBS, Germany). The particle size was calculated by the autocorrelation function of the ALV Sizer software.
Immunoprecipitation -3.1 µM VP1 pentamers were co-incubated for 4 hours at 25 °C with a 10
fold molar excess of GFP-VP2(A) or GFP, respectively. VP1 pentamers, GFP and GFP-VP2(A) were also incubated and served as controls. Protein-A-sepharose (Amersham Biosciences) was equilibrated with KB1 buffer and monoclonal antibodies (mab) directed against a conformational determinant of VP1-specific pentamers and appropriate capsoids (mab #17 kindly provided by Dr. M.
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Pawlita, Heidelberg, Germany) or GFP were coupled for 1 hour at 25 °C. After washing the sepharose two times with IP wash buffer (PBS, 0.1 % Triton X-100, pH 7.4), the above described protein samples were added and incubated for 1 hour at 25 °C. Unbound protein was removed by washing three times with IP wash buffer. Subsequently, the samples were analyzed by reducing 10% SDS-PAGE and Western-Blotting.
Fluorescence spectroscopy -To investigate the interaction between VP1 pentamers and the GFP-VP2(A) anchor construct, GFP fluorescence polarization measurements were carried out. GFP-VP2(A)
was incubated with an increasing amount of VP1-pentamers for 2 hours at 25 °C. GFP fluorescence polarization was measured at 510 nm (excitation 488 nm) for 10 minutes in a thermostatically controlled cell using a Fluoromax-3 spectrofluorimeter with autopolarizer (Jobin Yvon, Germany). The average signal was plotted against the VP1 pentamer concentration [M] and the dissociation constant (K d ) calculated according to equations 1A to 1C:
V 0 is the initial concentration of the VP1 pentamer, A 0 the concentration of the VP2 anchor, and VA the concentration of the complex. S stands for the starting (S 0 ) and the maximum signal (S max ).
In addition, the assembly of capsoids was monitored by measurement of light scatter of the sample at an angle of 90° and a wavelength of 360 nm. were ready for immediate TEM study on a Zeiss LEO 906E (LEO Elektronenmikroskopie GmbH,
Germany) operating at 80 kV.
RESULTS
Expression and purification of VP1 -The outer shell protein VP1 of murine polyomavirus was expressed in E. coli. The protein self-assembled into soluble pentamers in the cytoplasm of E. coli and was purified by ion exchange and size exclusion chromatography to homogeneity (data not shown). Neighbouring VP1 pentamers are covalently linked by disulfide bonds and calcium bridges in the capsoid (20, 21) , preventing disassembly of the structure in the absence of reducing and chelating agents. In order to avoid aggregation of VP1 pentamers by unspecific cross-linking, DTT and EDTA were present in all buffers throughout the purification process. Under these conditions, the protein was stable and could be stored at -80°C for several months. Interaction of the VP2 anchor constructs with the VP1 pentamer -The outer shell of the polyomavirus capsid is composed of 360 VP1 monomers, arranged in 72 pentamers on an icosahedral lattice (1) . VP2 binds to the hydrophobic pocket of the VP1 pentamer on the inward-facing side (15) . In order to evaluate, whether the C-terminal fragment of VP2 we used as an anchor molecule is able to interact with a VP1 pentamer, even when a protein like GFP is fused to the Nterminus, we performed gel filtration experiments. Free GFP-VP2(A) was clearly separated from the VP1 pentamer fraction. After incubation of GFP-VP2(A) with an equimolar amount of VP1 pentamer for 2 hours, both proteins co-eluted from the column (data not shown). To assess the specificity of the interaction between the VP1 pentamer and the VP2 anchor, we performed immunoprecipitation experiments. VP1 was co-incubated either with GFP-VP2(A) or GFP as a control, followed by immunoprecipitation with monoclonal antibodies against VP1 or GFP, respectively. SDS-PAGE and
VP2 anchor variants -

Expression and purification of VP2(B) anchor and conjugation to MTX -
Western-Blot analysis of the precipitated samples showed that GFP-VP2(A) and VP1 co-precipitated in both cases, revealing a tight interaction between the VP1 pentamer and the anchor (Fig. 2) . In contrast, no co-precipitation was observed after co-incubation of GFP and VP1, indicating that the attachment of GFP-VP2(A) to VP1 pentamers is highly specific and occurs via the C-terminal VP2
anchor. A corresponding fusion protein of GFP and the VP2(B) anchor gave similar results in analogous experiments (data not shown).
An important prerequisite for encapsulation of VP2 anchor constructs in VP1 capsoids is the sufficient stability of the interaction between the VP1 pentamer and the VP2 anchor over the time period which is required for complete capsoid assembly. The GFP fluorescence enabled us to investigate the interaction between VP1 pentamers and GFP-VP2(A) in detail by fluorescence polarization. Binding of the VP2 anchor to VP1 restricts the freedom of motion of the molecule, causing an increase in GFP fluorescence polarization. Using a 10-fold molar excess of VP1 pentamer over GFP-VP2(A) in our measurements, we observed 100 % binding (Fig. 3) . We Taken together, our results clearly demonstrate that the VP2 anchor comprising amino acids 251-297 of VP2 efficiently binds to the VP1 pentamer, even if covalently linked to a heterologous protein.
The association process is fast and results in a tight binding, which remains stable over a time range sufficient for capsoid assembly.
Encapsulation of VP2 anchor constructs -In order to achieve the encapsulation of VP2 anchorbound molecules into VP1 capsoids, a robust method allowing both the attachment of the VP2 anchor to the pentamer and the subsequent capsoid assembly within a short time frame was developed. For capsoid formation, DTT was removed from the pentamer solution to enable the formation of intrapentameric disulfide bonds, which stabilize assembled VP1 capsoids (14, 20, 21, 24) . In contrast to the assembly method described by Stehle and co-authors (20, 25) , we induced the assembly process by addition of high salt buffer to the pentamer solution. As shown in Figure 4A , this approach leads to capsoid formation in a concentration dependent way. At the lowest pentamer concentration examined (0.9 µM), the pentamers associated with a half-time of 170 seconds and the entire process was completed after 5 minutes. Increase of the protein concentration resulted in a faster assembly reaction. The course of assembly was also followed by PCS measurement, which showed a particle size of 8-9 nm for VP1 pentamers at the start of the reaction (Fig. 4B ) and a particle diameter of 35 nm for the resulting capsoids (Fig. 4C ).
The same method was applied for encapsulation of the different VP2 anchor constructs. Since we observed that higher molar ratios of anchor to pentamer inhibit capsoid assembly (data not shown), VP1 pentamers were incubated with a 6-fold molar excess of VP2(B)-MTX or a 7-fold molar excess of GFP-VP2(A), respectively (data not shown). After the formation of capsoids, free anchor was removed either by dialysis or size exclusion chromatography and homogeneously formed capsoids with a size of 35-40 nm were obtained (Fig. 5A) . Furthermore, size exclusion chromatography experiments revealed that no aggregates were present in the capsoid preparation (Fig. 5B) .
The encapsulated heterologous molecules confer additional absorption maxima to the VP1 spectrum at 310/377 nm for MTX, and at 488 nm for GFP. From UV-Vis spectra analysed at 488 nm, the number of GFP-VP2(A) molecules per VP1 capsoid was calculated to be about 104, corresponding to 144% of the theoretical loading maximum (data not shown). Analytical gel filtration indicated that GFP-VP2(A) was enclosed in the VP1 capsoid, since the anchor was found to co-elute with the VP1 peak (Fig. 5B) . A minor amount of GFP anchor molecules -probably bound unspecifically to the capsoid surface -eluted separately from the column (indicated by an arrow in Fig.   5B ). Integration of both GFP signals revealed a ratio of 2.6 : 1 (corresponding to 64 and 40 anchor molecules, respectively). The calculated loading ratio of GFP molecules per capsoid was 89% of the theoretical amount, assuming 72 VP1 pentamers per capsoid.
Immunoprecipitation experiments confirmed that, apart from encapsulated GFP-VP2(A), additional molecules either occur freely or unspecifically bound to the surface of the VP1 capsoids (data not shown). The gel filtration experiments suggested a rather weak interaction which was easy to disrupt during the chromatography process. After re-chromatography or extended dialysis of the capsoid fraction, no more free anchor was detectable by immunoprecipitation (data not shown).
Quantification of the encapsulated MTX by UV vis spectroscopy and gel filtration gave an average amount of 462 anchor molecules per VP1 capsoid (data not shown), whereas free VP2(B)-MTX was not observed. In comparison, none-conjugated MTX could not be encapsulated during VP1 assembly
due to the small molecule size and the cavity-containing morphology of the final capsoids (data not shown).
Electron microscopy of the loaded capsoids revealed a regular morphology, showing no significant differences to empty particles ( Fig. 6A-C) . Nevertheles, the capsoids GFP-VP2(A) showed minor particle formation in comparison to empty virus-like-particles and those that have encapsulated MTX ligands suggesting that the lower co-assembling efficiency within a given time-frame may depend on the charge distribution and the size of appropriate ligands, GFP versus MTX (Fig. 6C ).
Taken together, we have shown that the VP2-derived anchor molecule allows highly efficient encapsulation of GFP or MTX in recombinantly produced VP1 capsoids. After 30 minutes of uptake, GFP occurred in vesicular structures (Fig. 8, b ), which were labelled by VP1/Cy3 to the same extent (Fig. 8, bb) , showing that GFP and VP1/Cy3 were predominantly colocalized (Fig. 8, B) . After 1 hour of uptake a redistribution occurred: Fig. 8 , D is a phase contrast picture of the peripheral cytosol with 5 clearly distinctable vesicles (see framed detail) with markedly different fluorescence intensities of GFP (Fig. 8, E ) and VP1/Cy3 (Fig. 8, F) (Fig. 8, G MTX delivered via capsoids in a concentration range of 1 µM to 40 µM was also cytotoxic. In the range of 1 µM to 10 µM MTX the effect was concentration dependent, whereas no difference was observed between the effect of 10 µM and 40 µM encapsulated MTX (Fig. 9, B) . However, the time-span (Fig. 9, B ).
Protein delivery into cells via capsoids
Empty capsoids with a concentration of 1.8 mg/ml, corresponding to the capsoid concentration of 
DISCUSSION
In the present study, we examined the transfer of GFP and MTX into eukaryotic cells via polyoma virus-like particles, termed capsoids. The capsoids were entirely assembled in vitro from the recombinantly expressed outer shell protein VP1 purified to homogeneity. In order to achieve efficient and directed encapsulation, GFP and MTX were conjugated to a conserved stretch of the inner core protein VP2, which tightly binds to the inward-oriented side of VP1 pentamers (15, 24) and thus served as a molecular anchor prior to capsoid assembly. This delivery approach of using the interaction of two polyomavirus-specific proteins, VP1 and VP2, clearly differs from encapsulation strategies described by Schmidt et al. (26) . For packaging of foreign substances into VLPs, VP1 has to be engineered at an internal loop domain, whereas our approach left VP1 untreated and therefore offered more variability for the delivery of complete proteins independent of their structural interference with VP1-specific capsoid assembly. Purification of full-length VP2 of mouse polyomavirus is impossible because of the insolubility of the protein when expressed in E.coli. Refolding from inclusion bodies does not result in adequate amounts of soluble protein (22, 27) . Chen and co-workers (22) also showed that the 45 C-terminal residues of VP2 are sufficient for stable binding to the inner surface of the VP1 pentamer, which forms a cup-like cavity. Only residues 269-296 of VP2, which are part of a highly conserved stretch among different polyomaviruses, were clearly visible in the electron density map, revealing a hydrophobic interaction between a short α-helix and the VP1 pentamer.
Consequently, we decided to employ this fragment of VP2 as core of the anchor molecule. The residues N-terminal of Val 269, which is located at the top of the cavity formed by the VP1 pentamer, could not be resolved in the crystal structure, and the authors concluded that this part of VP2 might be somewhat flexible. We estimated that the VP2-mediated attachment of GFP to the inner surface of the VP1 pentamer would require a distance of at least 20 Å between Val 269 and the GFP-termini (located adjacent at one narrow side of the protein) in order to avoid steric hindrance. This notion favoured the fusion of GFP to the C-terminus of the VP2 anchor, as the corresponding Tyr 296 is located at the base of the pentamer. Since the C-terminal part of the resolved VP2 structure approaches the termini of VP1, which are very likely engaged in pentamer-pentamer interactions (20, 21) , the fusion of a 27 kDa protein at this site could possibly interfere with capsoid assembly. Therefore, a GFP-fusion to the N-terminus of the anchor molecule was considered as the better alternative, but obviously required an MTX has frequently been coupled to macromolecular carriers such as antibodies or synthetic polymers, using carbodiimides and N-hydroxysuccinimide (NHS) (29) . This active ester method, however, does not only lead to the desired MTX α-or γ-isomers, but also to bis-derivatives, MTX oligomers and several by-products, e.g. N-acylisourea derivatives due to rearrangement reactions (30) . Especially, the bis-derivatives have to be avoided, since bis(VP2-Cys-Lys-OMe)-MTX would be able to crosslink VP1, presumably causing problems in capsoid assembly. Formation of the described by-products was avoided by modifying a recently published coupling protocol of Riebeseel et al. (31) .
In case of loading substances to the interior of VP1 capsoids, an incubation and binding step, respectively, precedes capsoid assembly. The thermodynamic and kinetic stability of the binding of the anchor to the VP1 pentamer is a prerequisite for directed encapsulation of proteins and low molecular weight substances and in the end for an efficient loading of the capsoids. Aside, the sterical properties of the molecule to be encapsulated directly influence the encapsulation capacity. The interior of the capsoids has a volume of about 7150 nm 3 , which is enough space for a theoretical loading of 408 molecules of GFP. From this point of view, an amount of encapsulation near 100% should be achievable for the GFP-anchor molecule, assuming that a single capsoid is composed of 72 VP1 pentamers and one anchor binds to one pentamer.
In consideration of the determined dissociation constant of the VP1 pentamer anchor complex, a complete loading of the VP1 capsoid should be achievable employing a 10-fold molar access of the anchor. However, under these conditions, capsoid formation was not observed, presumably an indication for sterical influences and/ or an alteration of the VP1 pentamer VP1 pentamer interaction via an allosteric mechanism. Finally, 64 GFP molecules were enclosed in VP1 capsoids, which is lower than achieved using the VP1-WW system (14), but does not require molecular engineering of Neither GFP nor VP1/Cy3 fluorescence was found in the nuclei. Delivery of encapsulated molecules into the cytoplasm, however, was clearly demonstrated by the cytotoxic effect of MTX-loaded capsoids. The toxicity was time and concentration dependent as expected for an endocytotic uptake mechanism with subsequent endosomal degradation and sufficient release of MTX into the cytoplasm.
The high loading rate of the capsoids and the presence of VP2 anchor molecules may account for slight differences in intracellular processing, possibly through subtle changes in the particle surface conformation and/or a contribution of VP2 to viral entry (22) . An et al. (35) showed that recombinant virus-like particles assembled from different structural polyomavirus proteins i.e. VP1, VP1/2, VP1/3 or VP1/2/3, were equally internalized into 3T6 mouse cells and localized in the cytoplasm. The decision about the intracellular fate of the particles might be taken during and/or after internalization, when, depending on capsoid composition and structure, different intracellular pathways are addressed or initiated. It seems likely that there is no exclusiveness for one particular pathway, but maybe a shift of preferences occurs.
From an immunological point of view, we present here a device, which is very suitable for the in vivo delivery of full-length proteins like tumour antigens because heterologous polyoma capsoids displaying a CD8 T cell epitope were already able to protect inbred mice from lethal challenge with melanoma cells that express this relevant protein antigen (36) . For this reason, these capsoid-based immunotherapeutics may offer new opportunities for the treatment of cancer patients. (corresponds to VP1 pentamers) and at the end of the capsoid assembly process (C) (corresponds to VP1 capsoids). (intra -1 h, GFP/VP1-Cy3; G) or 3 hours (intra -3 h; C) of uptake at 37 °C. After 0.5 hours of uptake, similar fluorescence intensities for GFP and VP1-Cy3 (B) were found in vesicular structures, whereas at the later time points, the fluorescences of GFP and VP1-Cy3 become partly distributed to different vesicular compartments (C, E, and F). 
